Program
MIF Inhibitor IPG1094
Also written as “IPG1094 Tablets”, “IPG1094 300 mg SAD” and “IPG1094 600 mg SAD”.
Its studies are led by Nanjing Immunophage Biotech.
Furthest: phase 2, since Dec 25, 20233 company-led studies, 2 open or runningNext primary completion: Jan 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Immunophage Biotech | 32 open or running | phase 2since Dec 25, 2023 | Sep 16, 2021 | Jan 30, 2027phase 1 · NCT07679113 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 16, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05112159 · 76 enrolled · Australia
- Dec 25, 2023Phase 2 study in Solid TumorNCT06212076 · 60 planned · China
- Jun 25, 2026Phase 1 study in Healthy VolunteersNCT07679113 · 24 planned · China
Ahead
- Jan 30, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07679113
- Jul 9, 2027Primary completion: phase 2 study in Solid TumorNCT06212076
TargetBeta
MIF →read by rule
“An orally bioavailable inhibitor of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07679113Healthy Volunteers · China | 1 | Recruiting | Jan 30, 2027 | 24 |
| NCT06212076Solid Tumor · China | 2 | Recruiting | Jul 9, 2027 | 60 |
| NCT05112159Healthy Volunteers · Australia | 1 | Completed | Jul 25, 2022 | 76 |
How it is read
Names in the registry
- “IPG1094 Tablets”, 1 entry
- “IPG1094 300 mg SAD”, 1 entry
- “IPG1094 600 mg SAD”, 1 entry
- “IPG1094 900 mg SAD”, 1 entry
- “IPG1094 1200 mg SAD”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.